Natera’s Oncology Advancements and Market Potential Drive Buy Rating

Mark Massaro, an analyst from BTIG, reiterated the Buy rating on Natera. The associated price target was raised to $210.00.

Mark Massaro has given his Buy rating due to a combination of factors that highlight Natera’s promising advancements in oncology. The recent IMvigor011 trial results, presented at a prestigious symposium and published in a leading medical journal, demonstrated significant improvements in disease-free and overall survival rates for muscle-invasive bladder cancer patients using Natera’s Signatera test. This success not only validates the concept of treatment on molecular relapse but also suggests its potential applicability across various cancer types.
Furthermore, the study’s findings could lead to an extended adjuvant treatment window, enhancing patient outcomes. Natera’s strategic positioning in the immunotherapy space, not limited to a single drug, and its ongoing Checkmate 274 study with a different therapy, further strengthen its market potential. The company’s plan to seek FDA approval for a companion diagnostic status and the anticipation of favorable pricing from CMS underscore its growth prospects. These factors, combined with the large market opportunity and Natera’s first-mover advantage, support the raised price target and Buy rating.

In another report released on October 13, TD Cowen also maintained a Buy rating on the stock with a $215.00 price target.